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Abstract
The potential of noninvasive laser Doppler flowmetry
(LDF) and near infrared spectroscopy (NIRS) to detect
acute effects of different vascular-modifying agents on
perfusion and blood volume in tumors was evaluated.
C3H mouse mammary carcinomas (200 mm3) in the
rear foot of CDF1 mice were treated with flavone acetic
acid (FAA, 150 mg/kg), 5,6-dimethylxanthenone-4-
acetic acid (DMXAA, 20 mg/kg), combretastatin A-4
disodium phosphate (CA4DP, 250 mg/kg), hydralazine
(HDZ, 5 mg/kg), or nicotinamide (NTA, 500 mg/kg).
Tumor perfusion before and after treatment was eval-
uated by noninvasive LDF, using a 418C heated custom-
built LDF probewith four integrated laser /receiver units,
and tumor blood volume was estimated by NIRS, using
light guide coupled reflectance measurements at
800±10 nm. FAA, DMXAA, CA4DP, and HDZ significantly
decreased tumor perfusion by 50%, 47%, 73%, and 78%,
respectively. In addition, FAA, DMXAA, and HDZ sig-
nificantly reduced the blood volume within the tumor,
indicating that these compounds to some degree
shunted blood from the tumor to adjacent tissue, HDZ
being most potent. CA4DP caused no change in the
tumor blood volume, indicating that the mechanism of
action of CA4DP was vascular shut down with the blood
pool trapped in the tumor. NTA caused no change in
either tumor perfusion or tumor blood volume. We
conclude that noninvasive LDF and NIRS can determine
acute effects of vascular modifying agents on tumor
perfusion and blood volume.
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Introduction
Because tumor survival is critically dependent on a functional
vasculature, selective damaging of the vasculature of tumors
has been proposed as an attractive strategy against cancer
[1,2 ]. This treatment strategy is based on differences in the
endothelial cells between quiescent normal vessels in organs
and angiogenic active vessels in tumors. Today, several
vascular -damaging agents selectively targeting tumor ves-
sels have been developed. The vascular effect of these
agents has been documented by using various destructive
and invasive methods, including the 86RbCl extraction
technique, histologic assessment, and invasive laser Doppler
flowmetry (LDF) procedure [3-5].
Flavone acetic acid (FAA) and its analogue 5,6-dime-
thylxanthenone-4-acetic acid (DMXAA) are synthetic flavo-
noids with antitumor activity in a variety of experimental
tumors [6-8], mediated through a large and persistent
reduction in blood flow. This vascular effect is thought to be
mediated by induction of TNF- [9,10]. Combretastatin A-4
disodium phosphate (CA4DP) belongs to the group of
combretastatins initially isolated from the South African tree
Combretum caffrum. CA4DP is a tubulin-binding agent,
which causes pronounced vascular shutdown in experimen-
tal tumors [3,4,11-13]. It has been hypothesized that the
inhibition of tubulin polymerization affects endothelial cell
shape, leading to thrombus formation or changes in perme-
ability of the endothelium, but the exact mechanism of action
by CA4DP in vivo is still unknown [14,15]. The peripheral
vasodilator hydralazine (HDZ) and the amide derivative of
vitamin B3, nicotinamide (NTA), are useful control com-
pounds in tumor perfusion studies [16–19]. HDZ reduces
tumor perfusion by shunting blood from the tumor to adjacent
normal tissue [16], whereas NTA has been shown to increase
tumor blood flow in some but not all murine animal models
[17]. The exact mechanism of action of NTA is still unknown.
LDF provides noninvasive estimates of local blood
perfusion in superficial tissue [20]. The principle of this
technique is based on the change in wavelength (Doppler
shift ) of laser light reflected from moving red blood cells [21].
The Doppler -shifted light is converted into an arbitrary
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perfusion signal, which is approximately proportional to the
mean blood cell velocity multiplied by the concentration of
moving blood cells within the sampling volume.
Comparison of LDF with the 133xenon-clearance method
has shown high correlation [22-24]. Near infrared spectro-
scopy (NIRS) provides noninvasive estimates of the
hemoglobin concentration, because hemoglobin is a strong
absorber of near infrared light [25]. At 800 nm (the isosbestic
point of hemoglobin) the light absorption of a tissue is
proportional to the total hemoglobin concentration, disturbed
only marginally by other chromophores of the tissue [26,27].
The total hemoglobin concentration reflects the blood
volume, because the source of hemoglobin is the red blood
cells.
We have previously shown that LDF and NIRS can detect
angiogenic and antiangiogenic activity in a simple subcuta-
neous bFGF-pellet implantation model [28], and that NIRS
alone can provide estimates of the degree of vascularization
in solid tumors similar to the information obtained by
histologic Chalkley count analysis [29]. Here we describe a
novel, noninvasive, in vivomodel to evaluate acute effects of
vascular targeting agents on tumor perfusion and blood
volume, using LDF and NIRS.
Materials and Methods
Animal and Tumor Model
Female 10- to 14-week-old CDF1 mice were used. A
C3H mouse mammary carcinoma was transplanted and
grown on the right rear foot. Experiments were carried out
when tumors had reached approximately 200 mm3 in size.
Institutional guidelines for animal welfare and experimental
conduct were followed.
Drug Preparation
DMXAA (20 mg/kg), CA4DP (250 mg/kg), NTA (500
mg/kg), and HDZ (5 mg/kg) were dissolved in saline and
injected intraperitoneally ( i.p. ) at a volume of 0.02 ml /g
mouse body weight. FAA (150 mg/kg) was dissolved in 1%
Na2CO3 saline and injected i.p. at a volume of 0.02 ml/g
mouse body weight. NTA was purchased from Sigma
Chemical Co. (St. Louis, MO). All the remaining drugs were
generously supplied to us as follow: CA4DP (Oxigene
Europa AB, Lund, Sweden), DMXAA (Dr. William Denny,
University of Auckland, New Zealand), FAA (LIPHA, Lyon,
France), and HDZ (Ciba-Geigy, Copenhagen, Denmark) All
drugs were freshly prepared before each experiment. The
dose of each agent was chosen from previous experience
[17,30,31].
Experimental Design
All experiments were performed in a temperature-
controlled room (25±18C). A micromanipulator was used
to maintain a reproducible localization of the LDF and NIRS
probes perpendicular to and in close contact to the skin. Both
LDF and NIRS recordings were performed before treatment
and after 1 minute (clamped), 1 /2 hour (HDZ), 1 hour
(CA4DP and NTA), or 3 hours (FAA, DMXAA, and control ).
During LDF and NIRS recordings, animals were anesthe-
tized with ketamine/xylazine (5/50 mg/kg BW s.c. ) for
immobilization.
NIRS recordings The NIRS instrument was custom-built
(NMR Center, University of Copenhagen, Denmark) includ-
ing a xenon flash as the light source ( l4633 Hammamatsu,
near infrared spectrometer, Burlingame, CA) and a photo
diode (Siemens BPW21 photo diode, Hamburg, Germany)
as the light detector. Briefly, an optical filter (800±10 nm
interference filter ) in front of the xenon flash unit results in
emission of light with a wavelength of 800±10 nm. A
branched light guide (Y-shaped) accomplished the coupling
between the instrument and the animal. Backscattered light
is transmitted through the other branch of the Y-shaped
optical fiber to a second optical filter in front of the
photodiode. The 800±10-nm optical filters ensure detection
of light absorption of this specific wavelength only. In the
fused end of the light guide, the emitting and transmitting
fibers are randomly mixed, and the diameter of that part of
the probe is 3.0 mm. The NIRS instrument was calibrated
before each experimental session. The calibration was
stable over time and the calibration was controlled after
use. Full absorption, i.e., zero signal, was set to 0 reflectance
units (RU) and motility standard (Perimed, Stockholm,
Sweden) was calibrated to 70 RU. The NIRS value was
calculated as the mean of two recordings.
LDF recordings A Periflux laser Doppler flowmeter 4001 was
utilized. Laser light with the wavelength 780 nm is transmitted
to the skin by a 418C heated custom-built probe (6 mm o.d.,
250 m fiber separation, time constant 0.2 second, PF415-
175, Perimed). The probe (PF-415-175) has four integrated
lasers/ receiver units, which increase the measuring volume
and improve the reproducibility in tissues with spatial
variations in perfusion. The LDF apparatus was calibrated
Figure 1. Effects of vascular modifying agents on perfusion in a CH3 mouse
mammary carcinoma measured by noninvasive LDF. (Top ) Mean percent
change ( ±SD ) in relative perfusion. (Bottom ) No. + indicates the number
of tumors in which the perfusion was increased after treatment. No. 
indicates the number of tumors in which the perfusion was decreased after
treatment. Change (%) indicates the mean relative change in perfusion.
Statistical evaluations were performed using a paired two - tailed t test.
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to 250 perfusion units (PU) in motility standard (Perimed)
before each recording session. The calibration was stable
over time and the calibration was controlled after use. The
LDF signal was recorded continuously until a stable plateau
was obtained after approximately one minute. The LDF
probe was retracted if a sufficient total backscatter was not
obtained. The PU value was calculated as mean PU on the
plateau.
Results
Figure 1 shows the effect of vascular - targeting agents on
tumor perfusion measured by noninvasive LDF, while the
effect on tumor blood volume measured by noninvasive
reflectance NIRS is shown in Figure 2. Changes induced
by treatment were calculated for each individual tumor
relative to its pre- therapeutic value. The number of positive
and negative differences in each group is listed in both
figures.
The vascular -damaging agents FAA, DMXAA, and
CA4DP and the peripheral vasodilator HDZ significantly
decreased perfusion in C3H mouse mammary carcinoma by
50%, 47%, 73%, and 78%, respectively. In addition, FAA,
DMXAA, and HDZ significantly reduced the blood volume
within the tumor, indicating that these compounds to some
degree shunted blood from the tumor to adjacent tissue, HDZ
being most potent. CA4DP caused no change in the tumor
blood volume, indicating that the action of CA4DP was a
vascular shut down with the blood pool trapped in the tumor.
NTA caused no change in either tumor perfusion or tumor
blood volume.
Occlusion of the rear foot blood flow by an occlusive
clamp blocked tumor perfusion by 95%, without affecting
the blood volume, because the blood was trapped in the
tumor. The residual perfusion after clamping, median 8 PU
(range 5–15 PU) higher than the instrument zero, defined
the biological zero of the C3H mouse mammary carci-
noma. In the present work, the biological zero was
disregarded as a component in all measurements. The
controls showed no change in tumor perfusion or blood
volume.
Discussion
In the present study we demonstrated that LDF and NIRS are
useful tools to detect acute effects of different vascular -
targeting agents on tumor perfusion and blood volume in the
C3H mouse mammary carcinoma. In line with earlier
findings, we found that noninvasive LDF could determine
the rapid and extensive decrease in tumor perfusion by the
vascular -damaging agents FAA, DMXAA, and CA4DP and
the peripheral vasodilator HDZ. In fact, we found very similar
reduction in tumor perfusion by DMXAA (50% vs 50%),
CA4DP (73% vs 66%), and HDZ (78% vs 70%) as
found using the same tumor model and same time intervals
in recent studies using an invasive LDF procedure and the
86RbCl extraction technique [4,18].
By combining noninvasive LDF with noninvasive reflec-
tance NIRS we also obtained information about the blood
volume within the tumor. In accordance with studies using
magnetic resonance spectroscopy [32,33], we found that
HDZ significantly reduced the tumor blood volume. This
effect is due to a direct action of HDZ on vascular smooth
muscle cells in the vessels of normal tissues without dilating
tumor blood vessels, because they lack smooth muscle
cells. This results in a redistribution of the blood away from
the tumor, which is described as the vascular steal
phenomenon [16,34]. FAA and DMXAA also reduced
tumor perfusion by partially shunting the blood to adjacent
tissue. The action of FAA and DMXAA is thought to be a
result of an induction of TNF- in the tumor [8 ]. TNF- is
known to decrease tumor perfusion and cause hemorrhagic
necrosis [35]. In the ex vivo perfused tissue- isolated tumor
model, TNF- has been shown to increase the vascular
resistance in tumors [36]. In addition, histologic examina-
tion revealed that the vessel lumen was reduced after TNF-
 treatment. Other studies report a considerable swelling of
endothelial cells and significant intravascular recruitment of
polymorphonuclear cells in biopsies from patients after
TNF- treatment [37]. The decrease in blood volume
measured by NIRS following FAA and DMXAA treatment
indicates that less blood has access to the tumor, which is
likely to be the result of an increased geometric resistance
in the tumor.
In contrast, we showed that the vascular -damaging agent
CA4DP shut down perfusion while trapping the blood pool
inside the tumor volume. CA4DP does not induce TNF-
production in the tumor [12], but is believed to induce its
antivascular action in tumors by changing the shape or
detachment of endothelial cells, leading to thrombus
formation [14,15]. However, the exact mechanism of action
of CA4DP is still unknown. We found no significant effect of
NTA on either perfusion or blood volume. The lack of effect
on perfusion by NTA in C3H mouse mammary carcinoma
Figure 2. Effects of vascular - targeting agents on blood volume in a CH3
mouse mammary carcinoma measured by noninvasive NIRS. (Top ) Mean
percent change ( ±SD) in relative reflectance. Notice that an increase in
reflectance is due to less blood volume. (Bottom ) No. + indicates the
number of tumors in which the reflectance was increased after treatment. No.
 indicates the number of tumors in which the reflectance was decreased
after treatment. Change (% ) indicates the mean relative change in
reflectance. Statistical evaluations were performed using a paired two - tailed
t test.
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has been shown before by Horsman et al. using the RbCl
uptake procedure [38]. Furthermore, we obtained high LDF
values in untreated C3H mouse mammary carcinomas
(161±66 PU, mean±SD), indicating that the tumors initially
were well perfused, which makes a further increase in
perfusion more difficult.
The noninvasive LDF and NIRS methods as applied here
are topologically limited to superficial tumors, like on the rear
foot, because both reflectance NIRS and especially LDF
have limited measuring depths [39]. However, the present
study shows that our noninvasive LDF and NIRS methods
can determine the effects of vascular modifying agents on
tumor perfusion and blood volume. The LDF and NIRS
recordings in the control group showed considerable
variation, but in large groups of animals, the results were
consistent, as previously shown [28].
The nondestructive and noninvasive nature of our LDF
and NIRS equipment makes it attractive to use these
techniques to study different time-points of the activity of
vascular targeting agents in the future. We conclude that
LDF and NIRS are useful, noninvasive methods for evalua-
tion of acute effects of vascular modifying agents on tumor
perfusion and blood volume in C3H mammary carcinomas.
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